Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00082082
Status:
COMPLETED
Last Update Posted:
2008-01-15
First Post:
2004-04-28
Brief Title:
A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma
Sponsor:
SciClone Pharmaceuticals
Organization:
SciClone Pharmaceuticals
Study Overview
Official Title:
A Trial of Thymalfasin With Trans Arterial Chemo-Embolization TACE in the Treatment of Adult Patients With Unresectable Hepatocellular Carcinoma A Phase II Trial
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this Phase II trial is to compare the efficacy and safety of 6 months of treatment with thymalfasin plus trans arterial chemoembolization TACE with TACE alone in adult patients with non-surgical hepatocellular carcinoma HCC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None